LENSEY TILLER: Open Payments
NPI 1568915320 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$352 in 20 payments from 10 companies in 2025. Trend: 2023 $1,421 · 2024 $598 · 2025 $352
Food & beverage: $352
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 6 | $95 |
| Lilly USA, LLC | 3 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| ABBVIE INC. | 2 | $36 |
| Novo Nordisk Inc | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Amgen Inc. | 1 | $15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: ELIQUIS, MOUNJARO, QULIPTA, Ozempic, Auvelity, AIRSUPRA, PREVNAR 20, Veozah.
Industry payments across LA — which companies pay providers there.
